Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction

BACKGROUND: Angiotensin receptor neprilysin inhibitor (ARNi) therapy improves clinical outcomes in patients with heart failure and reduced left ventricular ejection fraction. However, ARNi therapy uptake remains modest, potentially in part due to perceived cost considerations of early transition fro...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:CJC Open
Autori principali: Grant, Andrew D.M., Chew, Derek S., Howlett, Jonathan G., Miller, Robert J.H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2020
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7710928/
https://ncbi.nlm.nih.gov/pubmed/33305203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cjco.2020.05.009
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi